Nimotuzumab in EGFR Highly Expressed Pancreatic Neuroendocrine Neoplasms
Nimotuzumab in EGFR Highly Expressed Pancreatic Neuroendocrine Neoplasms
Not yet recruiting · NCT05316480 · Registry updated 2022-04-07Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Nimotuzumab in EGFR Highly Expressed Pancreatic Neuroendocrine Neoplasms | Adenoma, Islet Cell, Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, adenoma, endocrine system disorder, epithelial neoplasm, malignant endocrine neoplasm, neoplasm, pancreas disorder, pancreatic neoplasm, pancreatic neuroendocrine neoplasm | Not yet recruiting | Phase 2 | 2022-04-07 | NCT05316480 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Fudan University | 653 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center; Pancreatic Cancer Institute, Fudan University | Shanghai | China | 7 |